Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1997
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AE04
|
| gptkbp:brand |
gptkb:nelfinavir
|
| gptkbp:CASNumber |
159989-64-7
|
| gptkbp:chemicalFormula |
C32H45N3O4S
|
| gptkbp:contraindication |
hypersensitivity to nelfinavir
|
| gptkbp:discoveredBy |
gptkb:Agouron_Pharmaceuticals
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:genericName |
yes
|
| gptkbp:halfLife |
3.5-5 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viracept
|
| gptkbp:interactsWith |
gptkb:rifampin
gptkb:St._John's_Wort oral contraceptives |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:patentExpired |
yes
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:sideEffect |
nausea
diarrhea rash |
| gptkbp:UNII |
X2BAK1J1FR
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Nelfinavir
gptkb:Agouron_Pharmaceuticals gptkb:nelfinavir |
| gptkbp:bfsLayer |
7
|